Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Historical Holders from Q2 2019 to Q3 2025

Symbol
AKRO on Nasdaq
CUSIP
00973Y108
Type / Class
Equity / COMMON STOCK
Shares outstanding
79.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
91.4M
Holdings value
$4.34B
% of all portfolios
0.006%
Grand Portfolio weight change
0%
Number of holders
257
Number of buys
115
Number of sells
-126
Average Value change %
0%
Average buys %
+0.002%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GENERAL ATLANTIC, L.P. 8.4% $244M 6.8M General Atlantic, L.P. Mar 31, 2025
JANUS HENDERSON GROUP PLC 7.9% -6.67% $298M -$21.8M 6.28M -6.8% JANUS HENDERSON GROUP PLC Sep 30, 2025
RTW INVESTMENTS, LP 7.3% -25% $287M -$48.2M 5.87M -14.4% RTW Investments, LP Jun 30, 2025
Deep Track Capital, LP 5.5% $209M 4.4M Deep Track Capital, LP Sep 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 5.3% +25% $202M $40M 4.25M +24.7% Wellington Management Group LLP Sep 30, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.8% $181M 3.81M T. Rowe Price Associates, Inc. Sep 30, 2025

Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 91.4M $4.34B -$45.1M $47.48 257
2025 Q2 92.1M $4.92B +$352M $53.36 253
2025 Q1 86.2M $3.5B +$531M $40.48 238
2024 Q4 74.2M $2.06B -$8.51M $27.82 188
2024 Q3 73M $2.09B +$38.3M $28.69 170
2024 Q2 71.8M $1.68B -$32.5M $23.46 152
2024 Q1 73.1M $1.85B +$381M $25.26 172
2023 Q4 67.3K $1.6M +$602K $23.69 2
2023 Q3 56.8M $2.87B +$62.9M $50.58 177
2023 Q2 56.2M $2.63B +$390M $46.69 154
2023 Q1 48M $1.84B -$63.2M $38.26 153
2022 Q4 48.5M $2.66B +$143M $54.80 155
2022 Q3 46.4M $1.58B +$488M $34.05 138
2022 Q2 34.7M $328M -$12M $9.45 102
2022 Q1 35M $496M -$4.32M $14.19 95
2021 Q4 35.2M $744M +$3.82M $21.15 92
2021 Q3 28M $626M +$6.66M $22.35 102
2021 Q2 25.7M $638M -$131M $24.81 94
2021 Q1 31.5M $913M +$20.6M $29.01 108
2020 Q4 30.8M $813M +$45.3M $25.80 92
2020 Q3 29M $892M +$220M $30.79 102
2020 Q2 21.8M $544M -$5.68M $24.92 75
2020 Q1 21.7M $460M +$62.8M $21.20 65
2019 Q4 19M $422M +$18.2M $22.19 57
2019 Q3 12.7M $288M +$54.8M $22.75 54
2019 Q2 10.7M $205M +$205M $19.15 48